htHD-FXRa

htHD-FXRa is an investigational **hepatocyte-targeted hydroxyl dendrimer therapeutic** being developed by **Ashvattha Therapeutics** for liver diseases, especially **nonalcoholic steatohepatitis**. The agent consists of a **farnesoid X receptor agonist** linked to a **hepatocyte-targeted hydroxyl dendrimer** designed for selective uptake into hepatocytes via the **asialoglycoprotein receptor**, thereby concentrating FXR agonism in the liver after systemic administration. In preclinical studies, this targeted conjugate reportedly reduced liver enzymes and improved NAFLD, steatosis, and fibrosis scores more effectively than unconjugated FXR agonist alone, with the development rationale of improving efficacy while lowering dose requirements and off-target toxicity.

Other names

hepatocyte-targeted hydroxyl dendrimer farnesoid X receptor agonisthepatocyte-targeted hydroxyl dendrimer therapeutic conjugated to an FXR agonist